Compare MXCT & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXCT | STIM |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | United States | United States |
| Employees | 91 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.0M | 140.6M |
| IPO Year | 2021 | 2018 |
| Metric | MXCT | STIM |
|---|---|---|
| Price | $1.24 | $1.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $5.50 | $3.00 |
| AVG Volume (30 Days) | 932.0K | ★ 1.3M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.25 |
| EPS | ★ N/A | N/A |
| Revenue | $33,026,000.00 | ★ $52,776,000.00 |
| Revenue This Year | N/A | $11.10 |
| Revenue Next Year | $18.50 | $11.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $0.80 |
| 52 Week High | $2.37 | $4.84 |
| Indicator | MXCT | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 65.10 | 51.70 |
| Support Level | $0.77 | $1.21 |
| Resistance Level | $1.30 | $1.42 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 68.00 | 84.55 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.